UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 111

Sortiert nach

A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy

Clinical gastroenterology and hepatology, 2014, Vol.12 (1), p.64-71

2014

Link zum Volltext

Verfügbarkeit prüfen

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

Gastroenterology (New York, N.Y. 1943), 2016-07, Vol.151 (1), p.110-119

2016

Link zum Volltext

Verfügbarkeit prüfen

Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates

Alimentary pharmacology & therapeutics, 2021-04, Vol.53 (7), p.810-820

2021

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions

Therapeutic Advances in Gastroenterology, 2018-01, Vol.11, p.1756284818772786-1756284818772786

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of Allopurinol on Clinical Outcomes in Inflammatory Bowel Disease Nonresponders to Azathioprine or 6-Mercaptopurine

Clinical gastroenterology and hepatology, 2007-02, Vol.5 (2), p.209-214

2007

Link zum Volltext

Verfügbarkeit prüfen

Predicting response after infliximab salvage in acute severe ulcerative colitis

Journal of gastroenterology and hepatology, 2018-07, Vol.33 (7), p.1347-1352

2018

Link zum Volltext

Verfügbarkeit prüfen

Quantification of Digestive Disease Damage in Crohn’s Disease, Are We There Yet With the Lémann Index?

Gastroenterology (New York, N.Y. 1943), 2021-09, Vol.161 (3), p.800-802

Sparrow, Miles P.

2021

Link zum Volltext

Verfügbarkeit prüfen

A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis

Frontiers in medicine, 2020-01, Vol.6, p.337-337

2020

Link zum Volltext

Verfügbarkeit prüfen

B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy

PloS one, 2016-07, Vol.11 (7), p.e0160103-e0160103

2016

Link zum Volltext

Verfügbarkeit prüfen

The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD

Journal of clinical medicine, 2023-06, Vol.12 (13), p.4382

2023

Link zum Volltext

Verfügbarkeit prüfen

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

Journal of Crohn's and colitis, 2018-02, Vol.12 (3), p.289-297

2018

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics

Journal of clinical medicine, 2022-10, Vol.11 (20), p.6173

2022

Link zum Volltext

Verfügbarkeit prüfen

Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results

Clinical gastroenterology and hepatology, 2016-09, Vol.14 (9), p.1302-1309

2016

Link zum Volltext

Verfügbarkeit prüfen

Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn’s disease?

Alimentary pharmacology & therapeutics, 2022-04, Vol.55 (8), p.1038-1039

2022

Link zum Volltext

Verfügbarkeit prüfen

A novel Monash Pouch diet in patients with an ileoanal pouch is tolerable and has favorable metabolic luminal effects

JGH open, 2023-12, Vol.7 (12), p.942-952

2023

Link zum Volltext

Verfügbarkeit prüfen

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?

World journal of gastroenterology : WJG, 2015-10, Vol.21 (40), p.11331-11342

2015

Link zum Volltext

Verfügbarkeit prüfen

Editorial: anti‐drug antibodies and the benefit of assay validation

Alimentary pharmacology & therapeutics, 2021-01, Vol.53 (1), p.194-195

2021

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target

Expert opinion on biological therapy, 2017-05, Vol.17 (5), p.613-621

Sparrow, Miles P.

2017

Link zum Volltext

Verfügbarkeit prüfen

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2019-08, Vol.17 (9), p.1655-1668.e3

2019

Link zum Volltext

Verfügbarkeit prüfen

Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?

Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2430-2431

2023

Link zum Volltext

Verfügbarkeit prüfen

Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels

Internal medicine journal, 2024-01, Vol.54 (1), p.139-148

2024

Link zum Volltext

Verfügbarkeit prüfen

Thiopurine immunomodulators in ulcerative colitis: moving forward with current evidence

Current drug targets, 2011-09, Vol.12 (10), p.1406

2011

Link zum Volltext

Verfügbarkeit prüfen

A Targeted Approach to Managing Chronic Pouchitis: Incorporating Accurate Phenotyping of Pouchitis and Assessment for Coexisting Dyssynergic Defecation

The American journal of gastroenterology, 2021-06, Vol.116 (6), p.1362-1362

2021

Link zum Volltext

Verfügbarkeit prüfen

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2020-03, Vol.51 (6), p.612-628

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(94)

Publikationsform

Sprache

Englisch
(110)
Japanisch
(11)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(86)
Gastroenterology & Hepatology
(68)
Humans
(64)
Inflammatory Bowel Disease
(47)
Inflammatory Bowel Diseases - Drug Therapy
(29)
Ulcerative Colitis
(28)
Female
(26)
Crohn's Disease
(25)
Gastroenterology
(22)
Adult
(21)
Infliximab
(20)
Male
(20)
Inflammatory Bowel Diseases
(17)
Azathioprine
(15)
Middle Aged
(15)
Monoclonal Antibodies
(15)
Treatment Outcome
(15)
Crohn Disease - Drug Therapy
(14)
Hepatology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions

Effect of Allopurinol on Clinical Outcomes in Inflammatory Bowel Disease Nonresponders to Azathioprine or 6-Mercaptopurine

Predicting response after infliximab salvage in acute severe ulcerative colitis

Quantification of Digestive Disease Damage in Crohn’s Disease, Are We There Yet With the Lémann Index?

A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis

B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy

The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics

Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results

Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn’s disease?

A novel Monash Pouch diet in patients with an ileoanal pouch is tolerable and has favorable metabolic luminal effects

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?

Editorial: anti‐drug antibodies and the benefit of assay validation

Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?

Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels

Thiopurine immunomodulators in ulcerative colitis: moving forward with current evidence

A Targeted Approach to Managing Chronic Pouchitis: Incorporating Accurate Phenotyping of Pouchitis and Assessment for Coexisting Dyssynergic Defecation

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

Suchergebnisse filtern